Navigation Links
Arigene Co., Ltd. Enters Into Amendment To Merger Agreement With Trimeris, Inc.
Date:11/17/2009

ls, and any other statements about Trimeris' managements' future expectations, beliefs, goals, plans or prospects constitute forward looking statements. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "anticipates," "expects," "estimates" and similar expressions) should also be considered to be forward looking statements. These forward looking statements involve known and unknown risks and uncertainties that may cause Trimeris' actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward looking statements. Important factors that may cause or contribute to such differences include uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Trimeris' stockholders will tender their stock in the offer; the risk that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, licensees, other business partners or governmental entities; transaction costs; whether results obtained in clinical studies or in preclinical studies will be indicative of results obtained in future clinical trials; whether Trimeris will be able to obtain regulatory approvals and such other factors as are set forth in the risk factors detailed from time to time in Trimeris' periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in Trimeris' Form 10-K filed with the Securities and Exchange Commission on March 13, 2009, which are incorporated herein by reference. The forward looking statements are made only as of the date of publication. Except as otherwise required by law, the Company specifically disclaims any obligation to update any o
'/>"/>
SOURCE Arigene Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sigma-Aldrich Enters Distribution Agreement With Stemgent, Inc. to Offer Lentivirus-Based Gene Delivery Products for Regenerative Medicine and Stem Cell Research
2. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
3. Accurays Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers
4. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
5. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
6. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
7. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
8. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
9. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
10. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
11. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre partner ... Virginia is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is ... husband, Dr. Cole Taylor , are avid scuba divers. "As ...
(Date:1/14/2014)... NineSigma , Inc., the leading innovation partner ... Summit , May 14-16, 2014 at the Global Center ... . This is the premier industry ... achievements through open innovation. Participants will learn how world-changing ...
(Date:1/14/2014)... , January 14, 2014 Equashield ... for hazardous drugs, today announced that it has ... straight year.   Equashield,s closed systems ... pharmacists, nurses and other medical professionals who prepare ...
Breaking Medicine Technology:Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2
... Group -, BRISBANE, Calif., May 28 ... clinical trials program through the,initiation of an additional ... The trial will assess BSI-201, the first ADP-ribose ... for the treatment,of uterine carcinosarcoma or malignant mixed ...
... C and LymphoStat-B(R) for lupus on track for ... potential launch in 2010 -,- ABthrax(TM) for inhalation anthrax on track to begin delivery fall ... ... - GSK to advance darapladib to Phase 3 for atherosclerosis -, ROCKVILLE, ...
Cached Medicine Technology:BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer 2Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 2Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 3Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 4Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 5Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 6Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 7Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 8Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 9Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 10Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 11
(Date:4/24/2014)... scientists a better understanding of drug interactions, which are ... , When two or more medications are taken at ... effectiveness of the other. Similarly, one drug may ... are a major cause of illness and hospitalization. ... scope of drug studies in humans. Limits come ...
(Date:4/24/2014)... (April 24, 2014) - Contact lenses coated with an antimicrobial ... infections, reports a study in Optometry and Vision ... of Optometry . The journal is published by ... Kluwer Health . , Studies in animals and now humans ... antimicrobial peptide melimine, according to the new research by Debarun ...
(Date:4/24/2014)... will bring together national experts to discuss solutions ... inaugural Brain Health Summit, titled "The Human Brain: ... Dr. Sandra Bond Chapman, founder and chief director ... Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) and ... Early Learning, U.S. Department of Education. The day ...
(Date:4/24/2014)... aspects, the corresponding terminology, and the relevance of ... in publications on randomized controlled trials (RCTs). This ... German Institute for Quality and Efficiency in Health ... final report. , Together with external experts, IQWiG ... glioblastoma, lung cancer, malignant melanoma, and pancreatic cancer. ...
(Date:4/24/2014)... is better to give than to receive at least ... study suggests. , The study found that 15- and 16-year-olds ... money to family members, are less likely to become depressed ... or keeping the money for themselves. , The researchers detail ... of Sciences . , The study focused on the ventral ...
Breaking Medicine News(10 mins):Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2
... behavior is linked to risk-taking, too, study finds, ... thrill-seeking behavior that makes people love skydiving, mountain-climbing ... an area of the brain that has been ... and Purdue University researchers studied volunteers who were ...
... LANSING, Mich. Women are 30 percent less likely ... can limit brain damage after a stroke, according to ... were presented Feb. 19 in San Diego at the ... and American Stroke Association. , Tissue plasminogen activator, or ...
... 19 Usinas,Siderurgicas de Minas Gerais S.A. - USIMINAS (OTC: USNZY; BOVESPA: USIM3,USIM5, USIM6; Latibex: ... USIMINAS Fourth Quarter 2008 Results Conference Call., ... the opening, ... 2009 at 10:00 AM EST in English, ...
... (Nasdaq: MYL ) today announced that its Vice ... NASDAQ Stock Market opening on Friday, Feb. 20 from 9:15 ... to celebrate the company,s switch from The New York Stock ... Dec. 29, 2008. The company is listed on the NASDAQ ...
... pancreatitis remains a disease with an unpredictable clinical ... the elevated intraabdominal pressure (IAP) after onset of ... is increasingly recognized as an important risk factor ... disease. However, It is still not clear whether ...
... Executives at Sage, an industry-,leading provider of ... records (EHR - http://tinyurl.com/ah9dgb ) system ... federally qualified,health centers, today joined with forward-looking ... the signing of the American,Reinvestment and Recovery ...
Cached Medicine News:Health News:Thrill-Seekers' Brains May Be Wired Differently 2Health News:Women less likely to receive critical care after a stroke, MSU researchers find 2Health News:Webcast Alert: Usinas Siderurgicas de Minas Gerais S.A. - USIMINAS Announces Fourth Quarter 2008 Earnings Results Webcast 2Health News:Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell 2Health News:Should intra-abdominal pressure measurement be a routine for all pancreatitis patients? 2Health News:Electronic Health Records (EHR) 'Leap Forward' Thanks to American Reinvestment and Recovery Act 2Health News:Electronic Health Records (EHR) 'Leap Forward' Thanks to American Reinvestment and Recovery Act 3
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Nucleus manipulator used during phacoemulsification. Used to break-up the nuclues within the capsular bag during two-handed phaco techniques. Blunt round tip, angled 40 degrees, 6mm from tip. Tip ang...
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
Medicine Products: